lung cancer

Event coverage

ASCO 2018 - Monday 4th June: BMS tries different tack as Mer...

Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow of data from its Keytruda checkpoint inhibitor drug at the conference in Chi

News

NICE recommends Pfizer’s Xalkori in rare lung cancer

NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).

News

Roche’s Tecentriq combo extends life in advanced NSCLC

Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).

News

AZ's Imfinzi hits second lung cancer trial goal

But AZ is anxiously waiting for results of MYSTIC trial

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Merck & Co's Keytruda could catch BMS' rival with new lung c...

Merck & Co's Keytruda blockbuster immunotherapy could have yet another use, after it significantly boosted survival in patients with untreated squamous non-small cell lu

News

Keytruda combo gets fast review in untreated lung cancer

Merck & Co's cancer drug Keytruda has been granted a priority review so that the immunotherapy medicine can be used in conjunction with chemotherapy to improve survival rates for untrea

ASCO 2018 - Monday 4th June: BMS tries different tack as Mer...

NICE recommends Pfizer’s Xalkori in rare lung cancer

Roche’s Tecentriq combo extends life in advanced NSCLC

AZ's Imfinzi hits second lung cancer trial goal

Merck & Co's Keytruda could catch BMS' rival with new lung c...

Keytruda combo gets fast review in untreated lung cancer

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

lung cancer

Editor's Picks